Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10945113 | 0.96 | KMT2A (0.54) | GAAPKML3MBTL1KMT2AMEN1 | |
| SCHEMBL2400768 | 0.84 | KMT2A (0.63) | GAAPKML3MBTL1KMT2AMEN1 | |
| SCHEMBL23977140 | 0.83 | TERT (0.57) | KMT2APOLBTERTCA1CA2 | |
| SCHEMBL5705415 | 0.82 | GAA (0.54) | GAAPKML3MBTL1KMT2AMEN1 | |
| SCHEMBL8914692 | 0.82 | SMN1; SMN2 (0.61) | L3MBTL1KMT2AMEN1CA1CA2 | |
| SCHEMBL782086 | 0.80 | GAA (0.56) | GAAPKML3MBTL1KMT2AMEN1 | |
| SCHEMBL1663647 | 0.80 | CA2 (0.58) | GAAKMT2AMEN1POLBTERT | |
| SCHEMBL29141123 | 0.80 | KMT2A (0.56) | GAAPKML3MBTL1KMT2AMEN1 | |
| SCHEMBL2399778 | 0.80 | MEN1 (0.61) | PKML3MBTL1KMT2AMEN1POLB | |
| SCHEMBL1821602 | 0.77 | GAA (0.61) | GAAPKML3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179496-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250099594-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-03-27 | — | — | US | disclosed |
| CN-118460536-A | Targeting composition | 阿布特斯生物制药公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240245784-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-07-25 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| CN-110741087-B | Targeting composition | 阿布特斯生物制药公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-13 | — | — | US | disclosed |
| US-20230110295-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-04-13 | — | — | US | disclosed |
| US-11427823-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-08-30 | — | — | US | disclosed |
| EP-3950004-A1 | TARGETED COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2022-02-09 | — | — | EP | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| US-20170107562-A1 | METHODS FOR NUCLEIC ACID SEQUENCING | Quantum-Si Incorporated (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107562-A1 | METHODS FOR NUCLEIC ACID SEQUENCING | Quantum-Si Incorporated (US) | 2017-04-20 | — | — | US | disclosed |
| US-9198872-B2 | Dendritic and hyperbranched polymers for cellular encapsulation and functionalization | UNIVERSITY OF MIAMI (US) | 2015-12-01 | — | — | US | disclosed |
| US-20120328673-A1 | DENDRITIC AND HYPERBRANCHED POLYMERS FOR CELLULAR ENCAPSULATION AND FUNCTIONALIZATION | UNIVERSITY OF MIAMI (US) | 2012-12-27 | — | — | US | disclosed |
| US-20110117020-A1 | IMAGING DENDRIMER NANOPROBES AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110117020-A1 | IMAGING DENDRIMER NANOPROBES AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110117020-A1 | IMAGING DENDRIMER NANOPROBES AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2009108947-A2 | IMAGING DENDRIMER NANOPROBES AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108947-A2 | IMAGING DENDRIMER NANOPROBES AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328673-A1 | DENDRITIC AND HYPERBRANCHED POLYMERS FOR CELLULAR ENCAPSULATION AND FUNCTIONALIZATION | TLR9, CD44, ITGAL | GAA 2275/4885PKM 1187/4885L3MBTL1 1299/4885 |
| US-20250099594-A1 | TARGETED COMPOSITIONS | HAVCR2, HDGF, NR1H4 | GAA 479/4885PKM 4126/4885L3MBTL1 953/4885 |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | HAVCR2, DCTD, POLRMT | GAA 514/4885PKM 4205/4885L3MBTL1 634/4885 |
| US-20110117020-A1 | IMAGING DENDRIMER NANOPROBES AND USES THEREOF | MSN, SELE, VEGFA | GAA 2791/4885PKM 1444/4885L3MBTL1 162/4885 |
| US-20240245784-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | GAA 514/4885PKM 4205/4885L3MBTL1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.